Revenio Group Corporation, Stock Exchange Release, April 20, 2016 at 8.20
THE ICARE ic100 HAS RECEIVED A SALES PERMIT FOR THE US MARKETS
Icare Finland Oy, a subsidiary of Revenio Group, filed a sales license application with the United States Food and Drug Administration FDA for its next-generation Icare ic100 tonometer in December 2015. Icare has now received notification that the FDA has granted it a permit to sell the device on the United States markets.
The Icare ic100 is a next-generation tonometer that will gradually replace the Icare TA01 tonometer introduced in 2003. The Icare ic100 tonometer has already been awarded a CE mark and sales have begun in Europe. The device also has sales permits in Australia and South Africa.
Icare's marketing team has been preparing for the product launch throughout the FDA licensing process. This will ensure that the company is fully prepared to begin the launch of the ic100 tonometer immediately and to deliver the first batch to the US markets.
For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi
DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.